PTC Therapeutics Stock Price, News & Analysis (NASDAQ:PTCT)

$15.79 0.06 (0.38 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$15.73
Today's Range$15.62 - $16.00
52-Week Range$8.12 - $22.00
Volume882,114 shs
Average Volume1.04 million shs
Market Capitalization$660.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:PTCT
  • CUSIP: N/A
  • Web: www.ptcbio.com
Debt:
  • Debt-to-Equity Ratio: 0.98%
  • Current Ratio: 3.08%
  • Quick Ratio: 2.97%
Sales & Book Value:
  • Annual Sales: $82.71 million
  • Price / Sales: 7.92
  • Book Value: $3.48 per share
  • Price / Book: 4.54
Profitability:
  • Trailing EPS: ($2.89)
  • Net Income: $-142,110,000.00
  • Net Margins: -75.64%
  • Return on Equity: -75.19%
  • Return on Assets: -31.76%
Misc:
  • Employees: 304
  • Outstanding Shares: 41,490,000
 

Frequently Asked Questions for PTC Therapeutics (NASDAQ:PTCT)

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Wednesday, November, 2nd. The biopharmaceutical company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.19. The biopharmaceutical company earned $23 million during the quarter, compared to the consensus estimate of $19.76 million. PTC Therapeutics had a negative net margin of 75.64% and a negative return on equity of 75.19%. PTC Therapeutics's revenue for the quarter was up 135.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. View PTC Therapeutics' Earnings History.

Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?

9 analysts have issued 12 month price objectives for PTC Therapeutics' stock. Their predictions range from $12.00 to $28.00. On average, they expect PTC Therapeutics' share price to reach $18.14 in the next year. View Analyst Ratings for PTC Therapeutics.

What are Wall Street analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:

  • 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (10/31/2017)
  • 2. Cowen and Company analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)
  • 3. Royal Bank Of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)
  • 4. Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)

Who are some of PTC Therapeutics' key competitors?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:

  • Michael Schmertzler, Independent Chairman of the Board (Age 65)
  • Stuart W. Peltz Ph.D., Chief Executive Officer, Director (Age 57)
  • Christine Marie Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer (Age 39)
  • Marcio Souza, Chief Operating Officer (Age 38)
  • Mark E. Boulding, Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 55)
  • Neil Almstead Ph.D., Executive Vice President, Research, Pharmaceutical Operations & Technology (Age 50)
  • Tuyen Ong, Chief Medical Officer (Age 42)
  • Allan S. Jacobson Ph.D., Independent Director (Age 71)
  • David P. Southwell, Independent Director (Age 56)
  • Glenn D. Steele Jr., M.D., Ph.D., Independent Director (Age 72)

Who owns PTC Therapeutics stock?

PTC Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include RTW Investments LP (8.42%), Dimensional Fund Advisors LP (1.27%), Point72 Asset Management L.P. (0.96%), Asymmetry Capital Management L.P. (861,920.47%), Pinnacle Associates Ltd. (0.77%) and Frontier Capital Management Co. LLC (0.60%). Company insiders that own PTC Therapeutics stock include Dawn Svoronos, Mark Rothera and Neil Gregory Almstead. View Institutional Ownership Trends for PTC Therapeutics.

Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?

PTC Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Asymmetry Capital Management L.P., Crestline Management LP, Chicago Equity Partners LLC, Oppenheimer & Co. Inc., South Dakota Investment Council, Canada Pension Plan Investment Board and Pinnacle Associates Ltd.. View Insider Buying and Selling for PTC Therapeutics.

Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?

PTC Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., American Century Companies Inc., RTW Investments LP, Sectoral Asset Management Inc, OxFORD Asset Management LLP, 361 Capital LLC, Fisher Asset Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.

How do I buy PTC Therapeutics stock?

Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTC Therapeutics stock can currently be purchased for approximately $15.79.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $660.51 million and generates $82.71 million in revenue each year. The biopharmaceutical company earns $-142,110,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. PTC Therapeutics employs 304 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 Corporate Ct, SOUTH PLAINFIELD, NJ 07080-2400, United States. The biopharmaceutical company can be reached via phone at +1-908-2227000 or via email at [email protected]


MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  567
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for PTC Therapeutics (NASDAQ:PTCT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $18.14 (14.90% upside)

Consensus Price Target History for PTC Therapeutics (NASDAQ:PTCT)

Price Target History for PTC Therapeutics (NASDAQ:PTCT)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017J P Morgan Chase & CoUpgradeUnderweight -> Neutral$15.00N/AView Rating Details
10/26/2017Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
10/25/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
10/25/2017Royal Bank Of CanadaSet Price TargetHold$15.00N/AView Rating Details
9/29/2017Barclays PLCLower Price TargetEqual Weight -> Equal Weight$22.00 -> $15.00HighView Rating Details
9/27/2017Citigroup Inc.Reiterated RatingBuy$28.00LowView Rating Details
9/26/2017Credit Suisse GroupReiterated RatingOutperform$25.00HighView Rating Details
8/23/2017William BlairInitiated CoverageMkt Perform -> Market Perform$17.00LowView Rating Details
1/10/2017Jefferies Group LLCReiterated RatingHold$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 -> $7.00N/AView Rating Details
4/17/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$39.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for PTC Therapeutics (NASDAQ:PTCT)

Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Earnings History by Quarter for PTC Therapeutics (NASDAQ PTCT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.89)($0.44)$28.78 million$47.96 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.88)($0.85)$27.93 million$26.50 millionViewListenView Earnings Details
3/16/201712/31/2016($1.07)($0.78)$24.69 million$25.20 millionViewN/AView Earnings Details
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)$10.93 million$9.22 millionViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
2017 EPS Consensus Estimate: ($2.87)
2018 EPS Consensus Estimate: ($2.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.96)($0.70)($0.83)
Q2 20172($0.93)($0.38)($0.66)
Q3 20173($0.89)($0.32)($0.68)
Q4 20173($0.88)($0.43)($0.70)
Q1 20181($0.81)($0.81)($0.81)
Q2 20181($0.65)($0.65)($0.65)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for PTC Therapeutics (NASDAQ PTCT)

Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 80.27%
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Insider Trades by Quarter for PTC Therapeutics (NASDAQ PTCT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Dawn SvoronosDirectorBuy25,000$13.49$337,250.00View SEC Filing  
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for PTC Therapeutics (NASDAQ PTCT)

Source:
DateHeadline
Traders Purchase High Volume of PTC Therapeutics Put Options (PTCT)Traders Purchase High Volume of PTC Therapeutics Put Options (PTCT)
www.americanbankingnews.com - November 17 at 2:54 AM
PTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by AnalystsPTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 7:44 PM
Comparing PTC Therapeutics (PTCT) & Vital Therapies (VTL)Comparing PTC Therapeutics (PTCT) & Vital Therapies (VTL)
www.americanbankingnews.com - November 16 at 1:08 PM
PTC Therapeutics, Inc. (PTCT) Upgraded to Neutral at J P Morgan Chase & CoPTC Therapeutics, Inc. (PTCT) Upgraded to Neutral at J P Morgan Chase & Co
www.americanbankingnews.com - November 16 at 9:20 AM
Daily Technical Summary Reports on Biotech Stocks -- Ophthotech, PTC ...Daily Technical Summary Reports on Biotech Stocks -- Ophthotech, PTC ...
www.prnewswire.com - November 14 at 7:00 AM
PTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $55.33 MillionPTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $55.33 Million
www.americanbankingnews.com - November 12 at 12:00 PM
PTC Therapeutics, Inc. (PTCT) Expected to Announce Earnings of -$0.45 Per SharePTC Therapeutics, Inc. (PTCT) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - November 10 at 9:20 AM
PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 9:05 AM
Edited Transcript of PTCT earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PTCT earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 9:23 AM
PTC Therapeutics (PTCT) Receives CRL for Atalurens NDA - StreetInsider.comPTC Therapeutics (PTCT) Receives CRL for Ataluren's NDA - StreetInsider.com
www.streetinsider.com - October 27 at 11:51 AM
PTC Therapeutics Receives Complete Response Letter for Atalurens NDAPTC Therapeutics Receives Complete Response Letter for Ataluren's NDA
finance.yahoo.com - October 27 at 11:51 AM
FDA declines to approve PTCs Duchenne drugFDA declines to approve PTC's Duchenne drug
finance.yahoo.com - October 27 at 11:51 AM
ETFs with exposure to PTC Therapeutics, Inc. : October 26, 2017ETFs with exposure to PTC Therapeutics, Inc. : October 26, 2017
finance.yahoo.com - October 27 at 11:51 AM
Todays Research Reports on Trending Tickers: Keryx Biopharmaceuticals and PTC TherapeuticsToday's Research Reports on Trending Tickers: Keryx Biopharmaceuticals and PTC Therapeutics
finance.yahoo.com - October 27 at 11:51 AM
Royal Bank Of Canada Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)Royal Bank Of Canada Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - October 25 at 11:08 PM
Cowen and Company Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)Cowen and Company Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - October 25 at 10:28 PM
PTC Therapeutics, Inc. (PTCT) to Release Earnings on TuesdayPTC Therapeutics, Inc. (PTCT) to Release Earnings on Tuesday
www.americanbankingnews.com - October 24 at 10:38 AM
PTC Therapeutics to Present at the Credit Suisse 26th Annual Healthcare ConferencePTC Therapeutics to Present at the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - October 24 at 8:51 AM
PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from AnalystsPTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 8:38 PM
PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results - PR Newswire (press release)PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results - PR Newswire (press release)
www.prnewswire.com - October 19 at 3:45 PM
PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial ResultsPTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results
finance.yahoo.com - October 19 at 3:45 PM
PTC Therapeutics, Sunfish Milestone Payment, Analysts Opinion, and October PDUFA DatePTC Therapeutics, Sunfish Milestone Payment, Analysts Opinion, and October PDUFA Date
finance.yahoo.com - October 16 at 4:06 AM
PTC THERAPEUTICS INVESTIGATION INITIATED BY...PTC THERAPEUTICS INVESTIGATION INITIATED BY...
www.benzinga.com - October 14 at 7:02 AM
PTC Therapeutics (PTCT) Announces Spinal Muscular Atrophy Program Advanced into Pivotal Study in SMA Patients - StreetInsider.comPTC Therapeutics (PTCT) Announces Spinal Muscular Atrophy Program Advanced into Pivotal Study in SMA Patients - StreetInsider.com
www.streetinsider.com - October 12 at 8:33 AM
Spinal Muscular Atrophy Program Advances into Pivotal Study in SMA PatientsSpinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients
finance.yahoo.com - October 12 at 8:32 AM
PTC Therapeutics, Inc. (PTCT) Stock Rating Lowered by Zacks Investment ResearchPTC Therapeutics, Inc. (PTCT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 11 at 10:18 AM
Is The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics? - BenzingaIs The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics? - Benzinga
www.benzinga.com - October 10 at 5:03 AM
PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 7:40 AM
PTC THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of PTC Therapeutics, Inc. - (PTCT)PTC THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of PTC Therapeutics, Inc. - (PTCT)
finance.yahoo.com - October 7 at 7:40 AM
PTC Therapeutics (PTCT) Reports RG7916 Increased SMN Protein Production in SUNFISH Clinical TrialPTC Therapeutics (PTCT) Reports RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial
www.streetinsider.com - October 5 at 10:52 PM
PTC Therapeutics (PTCT) Reports RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial - StreetInsider.comPTC Therapeutics (PTCT) Reports RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial - StreetInsider.com
www.streetinsider.com - October 5 at 5:51 PM
Why PTC Therapeutics, Inc. Dropped TodayWhy PTC Therapeutics, Inc. Dropped Today
www.fool.com - October 3 at 5:58 PM
RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular AtrophyRG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy
finance.yahoo.com - October 3 at 11:11 AM
Barclays PLC Trims PTC Therapeutics, Inc. (PTCT) Target Price to $15.00Barclays PLC Trims PTC Therapeutics, Inc. (PTCT) Target Price to $15.00
www.americanbankingnews.com - September 29 at 12:16 PM
PTC Therapeutics, Inc. (PTCT) Rating Reiterated by Royal Bank Of CanadaPTC Therapeutics, Inc. (PTCT) Rating Reiterated by Royal Bank Of Canada
www.americanbankingnews.com - September 29 at 9:08 AM
PTC Therapeutics gains after FDA panel votes against drug approvalPTC Therapeutics gains after FDA panel votes against drug approval
www.marketwatch.com - September 28 at 7:47 PM
PTC Therapeutics, Inc. (PTCT) Given Average Rating of "Hold" by BrokeragesPTC Therapeutics, Inc. (PTCT) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 27 at 8:44 PM
PTC Therapeutics (PTCT) "Buy" Rating Reiterated at Citigroup Inc.PTC Therapeutics' (PTCT) "Buy" Rating Reiterated at Citigroup Inc.
www.americanbankingnews.com - September 27 at 7:28 PM
Notable Wednesday Option Activity: LCI, PTCT, ACTANotable Wednesday Option Activity: LCI, PTCT, ACTA
www.thestreet.com - September 27 at 4:25 PM
Research Analysts Set Expectations for PTC Therapeutics, Inc.s Q1 2018 Earnings (PTCT)Research Analysts Set Expectations for PTC Therapeutics, Inc.'s Q1 2018 Earnings (PTCT)
www.americanbankingnews.com - September 27 at 11:10 AM
PTC Therapeutics Inc. (PTCT) Has Dropped To Over A 3-Month Low - NasdaqPTC Therapeutics Inc. (PTCT) Has Dropped To Over A 3-Month Low - Nasdaq
www.nasdaq.com - September 27 at 8:21 AM
FDA pours cold water on PTC Therapeutics Duchenne applicationFDA pours cold water on PTC Therapeutics' Duchenne application
finance.yahoo.com - September 26 at 7:11 PM
Here's Why PTC Therapeutics, Inc. Is Slipping TodayHere's Why PTC Therapeutics, Inc. Is Slipping Today
finance.yahoo.com - September 26 at 7:11 PM
PTC INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In PTC Therapeutics, Inc. To Contact The FirmPTC INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In PTC Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - September 26 at 7:11 PM
PTC Therapeutics (PTCT) "Outperform" Rating Reiterated at Credit Suisse GroupPTC Therapeutics' (PTCT) "Outperform" Rating Reiterated at Credit Suisse Group
www.americanbankingnews.com - September 26 at 6:20 PM
PTC Therapeutics, Inc. (PTCT) Earns Neutral Rating from J P Morgan Chase & CoPTC Therapeutics, Inc. (PTCT) Earns Neutral Rating from J P Morgan Chase & Co
www.americanbankingnews.com - September 26 at 5:38 PM
Heres Why PTC Therapeutics, Inc. Is Slipping TodayHere's Why PTC Therapeutics, Inc. Is Slipping Today
www.fool.com - September 26 at 1:32 PM
Heres Why Sarepta Stock is Up More Than 60% So Far in 2017Here's Why Sarepta Stock is Up More Than 60% So Far in 2017
www.zacks.com - September 25 at 9:32 AM
PTC Therapeutics: Sarepta Déjà Vu Or A Return To Scientific Standards? - Seeking AlphaPTC Therapeutics: Sarepta Déjà Vu Or A Return To Scientific Standards? - Seeking Alpha
seekingalpha.com - September 23 at 5:56 AM
Update in Lawsuit for Investors in NASDAQ: PTCT Shares Against PTC Therapeutics, Inc. Announced by Shareholders FoundationUpdate in Lawsuit for Investors in NASDAQ: PTCT Shares Against PTC Therapeutics, Inc. Announced by Shareholders Foundation
finance.yahoo.com - September 20 at 7:59 AM

Social Media

Financials

Chart

PTC Therapeutics (NASDAQ PTCT) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.